1. Home
  2. ESPR vs MCS Comparison

ESPR vs MCS Comparison

Compare ESPR & MCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$1.90

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Logo Marcus Corporation (The)

MCS

Marcus Corporation (The)

HOLD

Current Price

$18.69

Market Cap

590.8M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESPR
MCS
Founded
2008
1935
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Movies/Entertainment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
731.9M
590.8M
IPO Year
2013
1994

Fundamental Metrics

Financial Performance
Metric
ESPR
MCS
Price
$1.90
$18.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$8.75
$23.33
AVG Volume (30 Days)
7.4M
125.7K
Earning Date
05-07-2026
04-30-2026
Dividend Yield
N/A
1.72%
EPS Growth
60.71
N/A
EPS
N/A
0.77
Revenue
$403,135,000.00
$758,458,000.00
Revenue This Year
N/A
$12.05
Revenue Next Year
$12.81
$3.15
P/E Ratio
N/A
$24.18
Revenue Growth
21.31
3.11
52 Week Low
$0.73
$12.85
52 Week High
$4.18
$20.02

Technical Indicators

Market Signals
Indicator
ESPR
MCS
Relative Strength Index (RSI) 31.41 56.58
Support Level $1.34 $14.66
Resistance Level $2.08 $20.02
Average True Range (ATR) 0.16 0.55
MACD -0.01 -0.10
Stochastic Oscillator 11.89 30.89

Price Performance

Historical Comparison
ESPR
MCS

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

About MCS Marcus Corporation (The)

Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.

Share on Social Networks: